BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32675544)

  • 1. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation.
    Harada K; Wu CC; Wang X; Mizrak Kaya D; Amlashi FG; Iwatsuki M; Blum Murphy MA; Maru DM; Weston B; Lee JH; Rogers JE; Thomas I; Shanbhag N; Bhutani MS; Hofstetter WL; Nguyen QN; Ajani JA
    Ann Surg; 2020 Aug; 272(2):311-318. PubMed ID: 32675544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells.
    Harada K; Patnana M; Wang X; Iwatsuki M; Murphy MAB; Zhao M; Das P; Minsky BD; Weston B; Lee JH; Bhutani MS; Estrella JS; Shanbhag N; Ikoma N; Badgwell BD; Ajani JA
    Surg Today; 2020 Oct; 50(10):1223-1231. PubMed ID: 32409870
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Mantziari S; Pomoni A; Prior JO; Winiker M; Allemann P; Demartines N; Schäfer M
    BMC Med Imaging; 2020 Jan; 20(1):7. PubMed ID: 31969127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumor volume and total lesion glycolysis in esophageal carcinoma patients treated with definitive chemoradiotherapy.
    Yildirim BA; Torun N; Guler OC; Onal C
    Nucl Med Commun; 2018 Jun; 39(6):553-563. PubMed ID: 29668513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: multicenter study in Japan.
    Kitajima K; Kaida H; Nakatani K; Ishibashi M; Morita T; Nakajo M; Tamaki Y; Minamimoto R
    Nucl Med Commun; 2020 May; 41(5):443-451. PubMed ID: 32187159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Texture analysis of
    Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
    Franko J; Voynov G; Goldman CD
    Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy.
    Abdelhakeem A; Patnana M; Wang X; Rogers JE; Murphy MB; Sagebiel T; Ikoma N; Badgwell BD; Trail A; Estrella JS; Lu Y; Devine C; Ajani JA
    Oncology; 2021; 99(10):659-664. PubMed ID: 34352788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation.
    Suzuki A; Xiao L; Taketa T; Sudo K; Wadhwa R; Blum MA; Skinner H; Komaki R; Weston B; Lee JH; Bhutani MS; Rice DC; Maru DM; Erasmus J; Swisher SG; Hofstetter WL; Ajani JA
    Ann Oncol; 2013 Nov; 24(11):2854-9. PubMed ID: 23994746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database.
    Vlacich G; Samson PP; Perkins SM; Roach MC; Parikh PJ; Bradley JD; Lockhart AC; Puri V; Meyers BF; Kozower B; Robinson CG
    Cancer Med; 2017 Dec; 6(12):2886-2896. PubMed ID: 29139215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.
    Hofheinz F; Li Y; Steffen IG; Lin Q; Lili C; Hua W; van den Hoff J; Zschaeck S
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1485-1494. PubMed ID: 30949816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma.
    Abd El-Hafez YG; Moustafa HM; Khalil HF; Liao CT; Yen TC
    Oral Oncol; 2013 Mar; 49(3):261-8. PubMed ID: 23036774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: A multicenter, retrospective analysis.
    Pak K; Kim BS; Kim K; Kim IJ; Jun S; Jeong YJ; Shim HK; Kim SD; Cho KS
    Am J Otolaryngol; 2018; 39(1):1-5. PubMed ID: 29056243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes.
    Shao MS; Wong AT; Schwartz D; Weiner JP; Schreiber D
    Ann Thorac Surg; 2016 Jun; 101(6):2148-54. PubMed ID: 27016842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging and Response Evaluation to Neo-Adjuvant Chemoradiation in Esophageal Cancers Using 18FDG PET/ CT with Standardized Protocol.
    Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R; Zaman S
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):2003-2008. PubMed ID: 31350957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.
    Elimova E; Wang X; Etchebehere E; Shiozaki H; Shimodaira Y; Wadhwa R; Planjery V; Charalampakis N; Blum MA; Hofstetter W; Lee JH; Weston BR; Bhutani MS; Rogers JE; Maru D; Skinner HD; Macapinlac HA; Ajani JA
    Eur J Cancer; 2015 Nov; 51(17):2545-52. PubMed ID: 26321501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.
    Hayashi Y; Xiao L; Suzuki A; Blum MA; Sabloff B; Taketa T; Maru DM; Welsh J; Lin SH; Weston B; Lee JH; Bhutani MS; Hofstetter WL; Swisher SG; Ajani JA
    Eur J Cancer; 2012 Dec; 48(18):3396-404. PubMed ID: 22853875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
    Swisher SG; Winter KA; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1967-72. PubMed ID: 21507583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in Treatment of T1N0 Esophageal Cancer.
    Semenkovich TR; Hudson JL; Subramanian M; Mullady DK; Meyers BF; Puri V; Kozower BD
    Ann Surg; 2019 Sep; 270(3):434-443. PubMed ID: 31274653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.